Loading stock data…
IFRX
$2.10+0.03 (+1.45%)
Market ClosedLast close May 1
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
InflaRx N.V. in the Healthcare sector is trading at $2.10. The stock is currently near its 52-week high of $2.19, remaining 85.8% above its 200-day moving average. Technical signals show overbought RSI of 83 and bullish MACD crossover, explaining why IFRX maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 83) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.10
Potential Upside
5%
Whystock Fair Value$2.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Buy
Mean target$8.59+309.2%
Range$2.03 – $24.05
Fundamentals
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory dis...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$112.78M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.51
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-109.81%
Volume
Today's trading volume
1.13M
Recent News
April 2026 Penny Stocks To Watch For Potential Growth
The United States market has shown robust performance, rising 3.4% over the last week and 35% over the past year, with earnings projected to grow by 16% annually. In such a thriving market, identifying stocks with strong potential for growth often involves looking beyond well-known names to those that might not be on every investor's radar. Penny stocks, though an older term, remain relevant as they often represent smaller or newer companies that could offer surprising value and stability...
Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization
By Karen Roman Exec Edge sat down with Nadeem Moiz, Chief Executive Officer at Revance, to learn more about the company’s vision in aesthetics, skincare and therapeutics. Exec Edge: Tell us about Revance and the science-powered products within your portfolio across aesthetics, skincare and therapeutics. At Revance we believe that science based innovative products drive […]
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates
InflaRx (IFRX) delivered earnings and revenue surprises of +2.86% and -117.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
InflaRx Showcases Izicopan HS and CSU Data, Streamlines C5aR Strategy at Oppenheimer Conference
InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference. CEO Niels C. Riedemann said the company has recently streamlined its corporate strategy to
InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit
InflaRx (NASDAQ:IFRX) highlighted progress on its oral C5a receptor 1 (C5aR) antagonist izicopan and outlined upcoming development plans during a presentation at the Guggenheim Outlook Biotech Summit 2026. Chief Financial Officer Thomas Taapken and investor relations executive Jan Medina also discus